Compare ARK Genomic Revolution ETF (ARKG) vs Equinor ASA (EQNR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Equinor ASA — how do they compare? ARK Genomic Revolution ETF trades at $40.62, while Equinor ASA trades at $34.99 (market cap $78.18B). The key difference: Equinor ASA pays a 4.48% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Equinor ASA nearer its low. Which is the better fit depends on your goals.
| ARKG | EQNR | |
|---|---|---|
Sector | Sector/Thematic | Energy |
52-Week High | $43.57 | $42.40 |
52-Week Low | $23.09 | $22.41 |
Market Cap | — | $78.18B |
Enterprise Value | — | $89.94B |
Dividend Yield | — | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Equinor (EQNR) trades at $33.92, down 0.26% today, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating estimates in Q4 2025 and Q1 2026 but missing in Q3 2025. Recent news highlights strategic investments in Norwegian Continental Shelf projects and a share buy-back program. Valuation ratios appear attractive with a P/E of 15.35 and EV/EBITDA of 2.27, though net income margin has declined to 5.3% in 2025 from 19.29% in 2022.
EQNR presents a value opportunity with low valuation multiples and ongoing shareholder returns via dividends and buybacks. However, declining profitability and negative net cash flow trends pose risks. Analyst sentiment is mixed with 30% buy ratings but 57% hold, suggesting cautious optimism. Key catalysts include production growth from recent investments, while oil price volatility and execution risks remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
